Effects of H1-Antagonist on Cognition

This study has been completed.
Sponsor:
Information provided by:
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT00846950
First received: February 17, 2009
Last updated: February 18, 2009
Last verified: February 2009
  Purpose

The purpose of this study is to determine whether histamine is involved in memory and specific processes in human cognition.


Condition Intervention
Cognition
Drug: dexchlorpheniramine, lorazepam

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Official Title: Effects of H1-Antagonist on Stages of Human Information Processing

Resource links provided by NLM:


Further study details as provided by Maastricht University Medical Center:

Primary Outcome Measures:
  • P300 latency and LRP onset latency [ Time Frame: 1.5 hours after treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Words recalled [ Time Frame: 1.5 hours after treatment ] [ Designated as safety issue: No ]

Enrollment: 18
Study Start Date: December 2006
Study Completion Date: May 2007
Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: healthy volunteers Drug: dexchlorpheniramine, lorazepam

Detailed Description:

The neurotransmitter histamine appears to be involved in human cognitive performance. However, the exact role is very unclear. The role it plays in memory performance is highly disputed, as animal studies show decreased performance when the H1-receptor is blocked in the central nervous system while such findings in humans is scarce. To clarify the role of histamine in human memory and different processes in cognition, the effects of an H1-antagonist (dexchlorpheniramine) on memory, alertness and sensory and motor processes are measured. The study will be conducted according to a within subject cross-over design using healthy volunteers.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy as determined by a physician

Exclusion Criteria:

  • present or history of any neurological of psychiatric disease
  • present or history of any substance abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00846950

Locations
Netherlands
Faculty of Psychology and Neuroscience, Maastricht University
Maastricht, Limburg, Netherlands, 6229 ER
Sponsors and Collaborators
Maastricht University Medical Center
Investigators
Principal Investigator: Annemiek Vermeeren, Ph.D. Maastricht University hospital
  More Information

Additional Information:
No publications provided

Responsible Party: Effects of H1-antagonist on stages of human information processing, Dr. A. Vermeeren
ClinicalTrials.gov Identifier: NCT00846950     History of Changes
Other Study ID Numbers: 06-3-075
Study First Received: February 17, 2009
Last Updated: February 18, 2009
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Maastricht University Medical Center:
H1-antagonist
Event Related Potentials
Memory
Information processing
The effects of an H1 antagonist (dexchlorpheniramine) on human cognition

Additional relevant MeSH terms:
Lorazepam
Dexchlorpheniramine
Chlorpheniramine
Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hypnotics and Sedatives
Central Nervous System Depressants
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Antipruritics
Dermatologic Agents
Anti-Allergic Agents

ClinicalTrials.gov processed this record on September 14, 2014